| Autor: |
Hileman CO; Department of Medicine, Division of Infectious Diseases, MetroHealth Medical Center, Cleveland, Ohio, USA., Carman TL, Storer NJ, Labbato DE, White CA, McComsey GA |
| Jazyk: |
angličtina |
| Zdroj: |
AIDS research and human retroviruses [AIDS Res Hum Retroviruses] 2012 Jul; Vol. 28 (7), pp. 649-55. Date of Electronic Publication: 2011 Oct 17. |
| DOI: |
10.1089/AID.2011.0088 |
| Abstrakt: |
Omega-3 fatty acids decrease cardiovascular disease (CVD) mortality possibly due to antiinflammatory effect. Inflammation and endothelial dysfunction likely play a role in the heightened CVD risk in HIV. Our goal was to evaluate the effect of omega-3 fatty acids primarily on endothelial function and inflammation in HIV-infected adults with moderate CVD risk on stable antiretroviral therapy. We conducted a 24-week, randomized, double-blind, placebo-controlled study to evaluate the effect of omega-3-acid ethyl esters 1 g twice a day. Flow-mediated dilation (FMD) of the brachial artery, lipoproteins and markers of inflammation, endothelial activation, coagulation, and insulin resistance were measured at entry and week 24. There were no within- or between-group differences in change in FMD over 24 weeks (mean change in FMD -0.13% vs. 1.5% for treatment vs. placebo; p=0.21). There were no between-group differences in changes in lipoprotein levels or biomarkers tested, except soluble tumor necrosis factor receptor-I, which favored omega-3-acid ethyl esters. Omega-3 fatty acids did not improve endothelial function or activation, coagulation, or insulin resistance in virologically suppressed, HIV-infected men with moderate CVD risk; however, inflammation tended to improve. This suggests that omega-3 fatty acids may not be potent enough to counteract the enhanced inflammation and endothelial dysfunction due to HIV and antiretrovirals. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
